⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25334641 | 1.00 | — | — | |
| SCHEMBL21813430 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL10822821 | 0.97 | — | — | |
| SCHEMBL7608763 | 0.95 | MMP1 (0.50) | — | |
| SCHEMBL6935036 | 0.91 | MMP1 (0.47) | — | |
| SCHEMBL11963867 | 0.82 | — | — | |
| SCHEMBL16312318 | 0.80 | MMP1 (0.56) | — | |
| SCHEMBL28709191 | 0.80 | CYP2D6 (0.42) | — | |
| SCHEMBL1276559 | 0.80 | MMP1 (0.56) | — | |
| SCHEMBL331801 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321042-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2023-10-12 | — | — | US | claimed |
| EP-4181919-A1 | COMBINATION THERAPY | Pfizer Inc. (US) | 2023-05-24 | — | — | EP | claimed |
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| CN-102473961-B | Electrolyte including amide compound and electrochemical device including the same | LG CHEMICAL LTD | 2015-04-29 | — | — | CN | claimed |
| US-20120298931-A1 | VISCOSITY MODIFIER COMPOSITIONS AND METHODS | CARESTREAM HEALTH INC. | 2012-11-29 | — | — | US | claimed |
| WO-2012161900-A1 | CONDUCTIVE COMPOSITION COMPRISING VISCOSITY MODIFIER | CARESTREAM HEALTH, INC. (US) | 2012-11-29 | — | — | WO | claimed |
| CN-102473961-A | Electrolyte including amide compound and electrochemical device including the same | LG CHEMICAL LTD | 2012-05-23 | — | — | CN | claimed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2025128616-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230321042-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-4263294-A | ANTITUMOUR AGENTS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-04-21 | — | — | US | disclosed |
| EP-0014402-A1 | Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-08-20 | — | — | EP | disclosed |
| EP-0011302-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
| US-4051309-A | ALUMINUM HYDRIDE, VANADIUM OR TITANIUM HALIDE CARBONYL COMPOUND CATALYST | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1977-09-27 | — | — | US | disclosed |
| US-3953542-A | CATALYST OF VANADIUM OR TITANIUM HALIDE, ALUMINUM TRIHYDROCARBON, AND A CARBONYL COMPOUND | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1976-04-27 | — | — | US | disclosed |